8-K: Ensysce Biosciences Enters $10 Million Product Development Agreement with Galephar Pharmaceutical Research

Ensysce Biosciences has entered into a product development and commercial manufacturing agreement with Galephar Pharmaceutical Research, involving up to $10 million in research and development funding in exchange for stock and milestone-based payments.

Summary

• Ensysce Biosciences has entered into a Product Development and Commercial Manufacturing Supply Master Services Agreement with Galephar Pharmaceutical Research, effective January 12, 2025.
• Galephar will expend up to $10 million to support research and development, manufacture, packaging, and testing of Ensysce's PF614 drug product and PF614-MPAR project.
• In return, Ensysce will issue 1% of its outstanding shares to Galephar as a restricted stock grant, vesting against defined milestones over the project term, subject to a three-year lock-up (except in a change of control).
• Ensysce will also compensate Galephar's development costs against defined milestones in the form of 50% restricted stock or 50% freely tradeable shares at up to 1.2 times Galephar's actual costs, subject to the $10 million cap.
• The number of shares issued will be determined by the trailing five-day closing price divided by the payment amount, with no future variable pricing.
• If Ensysce raises more than $10 million from a third party for product development, up to 50% of payments to Galephar may be in cash, with a 30% gross-up to cover Galephar's tax liability.
• Ensysce grants Galephar a limited license of Intellectual Property to perform under the Agreement and supply sufficient quantities of certain active pharmaceutical ingredients.
• Galephar is required to supply Ensysce with other material and store certain products, material, supplies, batches and other items.
• All intellectual property related to Ensysce's products created under the Agreement will be the exclusive property of Ensysce.
• The agreement has a term of at least 15 years but is subject to termination following a material breach or insolvency of either party.

Sentiment

Score: 7

Explanation: The agreement is a positive development for Ensysce, providing funding and manufacturing support for its drug development programs. However, the dilution of existing shareholders and potential liabilities associated with the agreement temper the overall sentiment.

Positives

• Ensysce gains access to up to $10 million in funding for its PF614 and PF614-MPAR drug development programs.
• The structure of the agreement aligns Galephar's incentives with the successful development of Ensysce's products through milestone-based vesting of shares.
• Ensysce retains exclusive ownership of intellectual property related to its products developed under the agreement.
• The 15-year term provides long-term stability for the manufacturing and supply relationship.
• The agreement allows for flexibility in payment methods, including cash, if Ensysce raises additional capital.

Negatives

• Ensysce is diluting its existing shareholders by issuing shares to Galephar.
• The agreement requires Ensysce to provide a tax gross-up of 30% on cash payments to Galephar if Ensysce raises more than $10 million from a third party.
• Ensysce is granting Galephar a limited license to its intellectual property.
• The agreement includes a three-year lock-up on the restricted shares issued to Galephar, which could limit Galephar's ability to sell those shares.

Risks

• The success of the agreement depends on Galephar's ability to meet the defined milestones and develop the products effectively.
• There is a risk of material breach or insolvency of either party, which could lead to termination of the agreement.
• The agreement requires Ensysce to supply sufficient quantities of active pharmaceutical ingredients, which could be a challenge.
• The agreement is subject to regulatory approvals and compliance with cGMP standards.
• The agreement includes indemnification clauses that could expose Ensysce to potential liabilities.

Future Outlook

The agreement outlines a long-term collaboration between Ensysce and Galephar for the development and commercialization of Ensysce's drug products, with potential for future commercial supply agreements.

Management Comments

• No direct management quotes are provided in the document.

Industry Context

This agreement reflects a common industry practice of pharmaceutical companies outsourcing manufacturing and development activities to specialized contract research and manufacturing organizations (CROs/CMOs). It allows Ensysce to leverage Galephar's expertise and facilities while focusing on its core competencies in drug discovery and clinical development.

Comparison to Industry Standards

• The structure of the agreement, involving upfront equity, milestone-based payments, and cost reimbursement, is typical for pharmaceutical development partnerships.
• The 1.2x markup on Galephar's actual costs is within the range of industry-standard pricing for CRO/CMO services.
• Comparable companies that engage in similar outsourcing arrangements include smaller biotech firms partnering with larger CMOs for manufacturing and development support.
• The 15 year term is longer than many agreements, but is not unusual for agreements that include commercial supply.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of shares to Galephar.
• Employees may benefit from the increased funding and development activities.
• The agreement could lead to the development of new treatments for patients.
• Galephar will benefit from the revenue generated by the agreement.

Next Steps

• The parties will enter into other agreements in furtherance of the project, such as a Quality Agreement and Commercial Supply Agreement.
• The Parties will establish a Joint Development Committee (JDC), comprising two (2) representatives from each of the Parties, to oversee the Product transfer to the Facility, and its subsequent development and manufacture.

Key Dates